Intellia Therapeutics, Inc. (NTLA) Stake Boosted by Alliancebernstein L.P.
Alliancebernstein L.P. increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 17.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,400 shares of the company’s stock after acquiring an additional 4,600 shares during the period. Alliancebernstein L.P. owned about 0.08% of Intellia Therapeutics worth $486,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in NTLA. UBS Group AG grew its holdings in shares of Intellia Therapeutics by 432.0% in the first quarter. UBS Group AG now owns 60,935 shares of the company’s stock valued at $859,000 after acquiring an additional 49,480 shares in the last quarter. American Century Companies Inc. bought a new position in shares of Intellia Therapeutics in the second quarter valued at approximately $583,000. Vanguard Group Inc. grew its holdings in shares of Intellia Therapeutics by 3.9% in the first quarter. Vanguard Group Inc. now owns 904,708 shares of the company’s stock valued at $12,747,000 after acquiring an additional 33,925 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Intellia Therapeutics by 73.0% in the second quarter. Bank of New York Mellon Corp now owns 54,802 shares of the company’s stock valued at $876,000 after acquiring an additional 23,126 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Intellia Therapeutics by 176.1% in the second quarter. Wells Fargo & Company MN now owns 30,215 shares of the company’s stock valued at $483,000 after acquiring an additional 19,270 shares in the last quarter. 47.77% of the stock is owned by institutional investors.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) opened at $21.94 on Friday.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The business had revenue of $7.30 million for the quarter, compared to the consensus estimate of $5.83 million. During the same quarter in the prior year, the business earned ($0.22) earnings per share. Intellia Therapeutics’s revenue for the quarter was up 49.0% on a year-over-year basis. sell-side analysts forecast that Intellia Therapeutics, Inc. will post -1.68 earnings per share for the current fiscal year.
Several equities analysts have recently issued reports on the company. Oppenheimer Holdings, Inc. assumed coverage on Intellia Therapeutics in a report on Tuesday, July 18th. They issued a “market perform” rating for the company. Credit Suisse Group upped their price objective on Intellia Therapeutics from $24.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday. Chardan Capital downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 price objective on the stock. in a research note on Tuesday, August 29th. Cann reiterated a “hold” rating on shares of Intellia Therapeutics in a research note on Tuesday, August 1st. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $36.00 price objective on shares of Intellia Therapeutics in a research note on Saturday, July 22nd. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $30.17.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.